Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.

Key facts

Study ID

NCT00624351

Run by

UCB Pharma

People needed

227

Starts

2008-01-01

Expected to finish

2009-08-01

Last updated by the study team

2011-09-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive ANA result at visit 1
• Current diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology revised criteria such that at least 4 of the 11 criteria are met
• Active moderate or severe SLE disease activity as demonstrated by British Isles Lupus Assessment Group (BILAG) A level disease activity in at least one body/organ system or BILAG B level disease activity in at least two body/organ systems if no BILAG A level disease is present
• If on antimalarials, dose regimen must be stable for 4 weeks prior to study entry.

You may not qualify if…

• Patients receiving any live vaccination within 2 weeks prior to visit 1 or during the course of the study
• Active severe SLE disease activity which involves the central nervous system (CNS) (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures
• Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher World Health Organization (WHO) nephritis) or serum creatinine >2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria >3.5gm/day
• Patients with a history of anti-phospholipid antibody syndrome AND use of oral anticoagulants or anti-platelet treatment
• Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection

Where it is running

• Study site — Brooklyn, New York, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Durham, North Carolina, United States
• Study site — Wilmington, North Carolina, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Dallas, Texas, United States
• Study site — Arlington, Virginia, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Brussels, Belgium
• Study site — Leuven, Belgium
• Study site — Curitiba, Brazil
• Study site — Goiânia, Brazil
• Study site — Porto Alegre, Brazil
• Study site — Rio de Janeiro, Brazil
• Study site — São Paulo, Brazil
• Study site — Sorocaba, Brazil
• Study site — Chai Wan, Hong Kong
• Study site — Shatin, Hong Kong
• Study site — Debrecen, Hungary
• Study site — Zalaegerszeg, Hungary
• Study site — Bangalore, India
• Study site — Hyderabad, India
• Study site — Ludhiana, India
• Study site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.